Section Arrow
GNFT.NASDAQ
- Genfit SA
Quotes are at least 15-min delayed:2025/11/16 13:31 EST
Regular Hours
Last
 4.25
+0.1 (+2.41%)
Day High 
4.31 
Prev. Close
4.15 
1-M High
4.4098 
Volume 
30.79K 
Bid
3.65
Ask
4.3
Day Low
4.2 
Open
4.26 
1-M Low
3.645 
Market Cap 
207.51M 
Currency USD 
P/E 103.08 
%Yield -- 
10-SMA 4.02 
20-SMA 4.13 
50-SMA 4.08 
52-W High 4.75 
52-W Low 2.55 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.78/-0.53
Enterprise Value
213.06M
Balance Sheet
Book Value Per Share
1.22
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
67.00M
Operating Revenue Per Share
0.50
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1063+0.0011+1.05%-- 
CYPHCypherpunk Technologies Inc.2.75+0.99+56.25%-- 
IVVDInvivyd2.35+0.58+32.77%-- 
APLTApplied Therapeutics0.2183-0.0517-19.15%-- 
RXRXRecursion Pharmaceuticals4.14-0.19-4.39%-- 
Quotes are at least 15-min delayed:2025/11/16 13:31 EST
Industry overview quotes are at least 15 minutes delayed
Business Description
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.